Dowden Nathan J 4

What Happened
Nathan J. Dowden, President & Chief Operating Officer of Entrada Therapeutics (TRDA), sold a total of 15,010 shares in two open-market transactions: 3,116 shares on 2026-03-09 at a weighted average price of $13.02 for proceeds of $40,583, and 11,894 shares on 2026-03-10 at a weighted average price of $13.05 for proceeds of $155,188. Total proceeds from both sales were about $195,771. These were sales (not purchases) and were executed under a pre-established trading plan.

Key Details

• Transaction dates and prices:
  • 2026-03-09: 3,116 shares sold, weighted avg $13.02 (prices in range $13.00–$13.09). (Footnote F2)
  • 2026-03-10: 11,894 shares sold, weighted avg $13.05 (prices in range $13.00–$13.20). (Footnote F3)
• Total shares sold: 15,010; total proceeds: ≈ $195,771.
• Shares owned after the transactions: Not disclosed in the information provided here (see the full Form 4 for post-transaction holdings).
• Footnotes: F1 — transactions were effected under a Rule 10b5-1 trading plan adopted March 7, 2025. F2/F3 — reported prices are weighted averages across multiple trades; the filer can provide a price-by-price breakdown on request.
• Filing: Form 4 filed 2026-03-11; appears timely relative to the trade dates.

Context
A Rule 10b5-1 plan is a pre-arranged trading program that allows insiders to sell shares on a set schedule and is commonly used to avoid the appearance of trading on non-public information. Sales under a 10b5-1 plan are typically considered routine; they do not by themselves indicate management’s view of the company’s prospects. Purchases tend to be more informative about insider confidence than scheduled sales.